Hodgkin’s Lymphoma in Older Patients: an Orphan Disease?

Por Thyss, Antoine, Saada, Esma, Gastaud, Lauris, Peyrade, Frédéric, Re, Daniel
Publicado em 2014

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer

Por Thariat, Juliette, Launay-Vacher, Vincent, Italiano, Antoine, Santini, José, Peyrade, Frederic
Publicado no NDT Plus (2008)

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation

Por Peyrade, Frederic, Re, Daniel, Ginet, Clemence, Gastaud, Lauris, Allegra, Maryline, Ballotti, Robert, Thyss, Antoine, Zenz, Thorsten, Auberger, Patrick, Robert, Guillaume
Publicado em 2013

Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib

Por Bailleux, Caroline, Robert, Guillaume, Ginet, Clémence, Re, Daniel, Thyss, Antoine, Sudaka, Isabelle, Peyrottes, Isabelle, Hofman, Paul, Auberger, Patrick, Peyrade, Frederic
Publicado no Oncoscience (2014)

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphom...

Por Tardy, Magalie P., Gastaud, Lauris, Ojeda-Uribe, Mario, Boscagli, Annick, Caruso, Salvatore, Skaf, Richard, Gutnecht, Jean, Thyss, Antoine, Peyrade, Frédéric
Publicado no Exp Hematol Oncol (2015)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics

Por Refae, Sadal, Gal, Jocelyn, Brest, Patrick, Giacchero, Damien, Borchiellini, Delphine, Ebran, Nathalie, Peyrade, Frederic, Guigay, Joël, Milano, Gérard, Saada-Bouzid, Esma
Publicado no Sci Rep (2020)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics

Por Refae, Sadal, Gal, Jocelyn, Brest, Patrick, Giacchero, Damien, Borchiellini, Delphine, Ebran, Nathalie, Peyrade, Frederic, Guigay, Joël, Milano, Gérard, Saada-Bouzid, Esma
Publicado no Sci Rep (2020)

Interleukin-10 Gene Polymorphisms are Associated With Freedom From Treatment Failure for Patients With Hodgkin Lymphoma

Por Schoof, Nils, Franklin, Jeremy, Fürst, Robert, Zander, Thomas, von Bonin, Frederike, Peyrade, Frederic, Trümper, Lorenz, Diehl, Volker, Engert, Andreas, Kube, Dieter, Re, Daniel
Publicado em 2013

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway

Por Robert, Guillaume, Jullian, Valérie, Jacquel, Arnaud, Ginet, Clémence, Dufies, Maeva, Torino, Stephanie, Pottier, Anaïs, Peyrade, Frederic, Tartare-Deckert, Sophie, Bourdy, Geneviève, Deharo, Eric, Auberger, Patrick
Publicado em 2012

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03

Por Fayette, Jerome, Guigay, Joel, Tourneau, Christophe Le, Degardin, Marian, Peyrade, Frederic, Neidhardt, Eve-Marie, Sablin, Marie-Paule, Even, Caroline, Orlandini, Florence, Juzyna, Béata, Bellera, Carine
Publicado no Oncotarget (2017)

DPD status and fluoropyrimidines-based treatment: high activity matters too

Por Chamorey, Emmanuel, Francois, Eric, Etienne, Marie-Christine, Ferrero, Jean-Marc, Peyrade, Frederic, Barranger, Emmanuel, Bozec, Alexandre, Largillier, Rémy, Cassuto, Ophelie, Viotti, Julien, Schiappa, Renaud, Milano, Gérard
Publicado no BMC Cancer (2020)

Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement

Por Barrière, Jérôme, Audigier-Valette, Clarisse, Borchiellini, Delphine, Hoch, Benjamin, Castelnau, Olivier, Francois, Eric, Gastaud, Lauris, Skaf, Richard, Berdah, Jean-François, Marie, Wislez, Lescaut, Willy, Peyrade, Frédéric, Cluzeau, Thomas, Cassuto, Ophélie, Carles, Michel
Publicado no Bull Cancer (2021)

Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study

Por Montaudié, Henri, Viotti, Julien, Combemale, Patrick, Dutriaux, Caroline, Dupin, Nicolas, Robert, Caroline, Mortier, Laurent, Kaphan, Régis, Duval-Modeste, Anne-Bénédicte, Dalle, Stéphane, De Quatrebarbes, Julie, Stefan, Andrea, Brunet-Possenti, Florence, Kogay, Maria, Picard-Gauci, Alexandra, Poissonnet, Gilles, Peyrade, Frédéric
Publicado no Oncotarget (2020)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies

Por Cabannes‐Hamy, Aurélie, Peyrade, Frederic, Jardin, Fabrice, Emile, Jean‐François, Delwail, Vincent, Mounier, Nicolas, Haioun, Corinne, Perrot, Aurore, Fitoussi, Olivier, Lara, Diane, Delarue, Richard, André, Marc, Offner, Fritz, Ghesquières, Hervé, Pascal, Laurent, Soussain, Carole, Lazarovici, Julien, Schiano, Jean‐Marc, Gaulard, Philippe, Tilly, Hervé, Thieblemont, Catherine
Publicado no Cancer Med (2018)

FCGR3A/2A polymorphisms and Diffuse Large B-cell Lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1,134 patients from two prospective cohorts

Por Ghesquières, Hervé, Larrabee, Beth R., Haioun, Corinne, Link, Brian K., Verney, Aurélie, Slager, Susan L., Ketterer, Nicolas, Ansell, Stephen M., Delarue, Richard, Maurer, Matthew J., Fitoussi, Olivier, Habermann, Thomas M., Peyrade, Fréderic, Dogan, Ahmet, Molina, Thierry J., Novak, Anne J., Tilly, Hervé, Cerhan, James R., Salles, Gilles
Publicado no Hematol Oncol (2016)

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study

Por Lazarovici, Julien, Dartigues, Peggy, Brice, Pauline, Obéric, Lucie, Gaillard, Isabelle, Hunault-Berger, Mathilde, Broussais-Guillaumot, Florence, Gyan, Emmanuel, Bologna, Serge, Nicolas-Virelizier, Emmanuelle, Touati, Mohamed, Casasnovas, Olivier, Delarue, Richard, Orsini-Piocelle, Frédérique, Stamatoullas, Aspasia, Gabarre, Jean, Fornecker, Luc-Matthieu, Gastinne, Thomas, Peyrade, Fréderic, Roland, Virginie, Bachy, Emmanuel, André, Marc, Mounier, Nicolas, Fermé, Christophe
Publicado no Haematologica (2015)

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Por Maurer, Matthew J., Ghesquières, Hervé, Jais, Jean-Philippe, Witzig, Thomas E., Haioun, Corinne, Thompson, Carrie A., Delarue, Richard, Micallef, Ivana N., Peyrade, Frédéric, Macon, William R., Jo Molina, Thierry, Ketterer, Nicolas, Syrbu, Sergei I., Fitoussi, Olivier, Kurtin, Paul J., Allmer, Cristine, Nicolas-Virelizier, Emmanuelle, Slager, Susan L., Habermann, Thomas M., Link, Brian K., Salles, Gilles, Tilly, Hervé, Cerhan, James R.
Publicado em 2014

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

Por Maurer, Matthew J., Ghesquières, Hervé, Link, Brian K., Jais, Jean-Philippe, Habermann, Thomas M., Thompson, Carrie A., Haioun, Corinne, Allmer, Cristine, Johnston, Patrick B., Delarue, Richard, Micallef, Ivana N., Peyrade, Frederic, Inwards, David J., Ketterer, Nicolas, Farooq, Umar, Fitoussi, Olivier, Macon, William R., Molina, Thierry J., Syrbu, Sergei, Feldman, Andrew L., Slager, Susan L., Weiner, George J., Ansell, Stephen M., Cerhan, James R., Salles, Gilles A., Witzig, Thomas E., Tilly, Hervé, Nowakowski, Grzegorz S.
Publicado no J Clin Oncol (2018)